

(19)



(11)

EP 3 456 351 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
20.03.2019 Bulletin 2019/12

(51) Int Cl.:
A61K 39/395 (2006.01) **C07K 16/00** (2006.01)
C07K 16/18 (2006.01) **C12P 21/08** (2006.01)

(21) Application number: **18188349.7**

(22) Date of filing: **03.04.2007**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

- **KANEKO, Yoshikatsu**
New York, NY 10065 (US)
- **NIMMERJAHN, Falk**
91054 Erlangen (DE)

(30) Priority: **05.04.2006 US 789384 P**

(74) Representative: **Goodfellow, Hugh Robin**
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA (GB)

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
14183260.0 / 2 815 768
07754846.9 / 2 010 566

Remarks:

- This application was filed on 09-08-2018 as a divisional application to the application mentioned under INID code 62.
- Claims filed after the date of filing of the application/date of receipt of the divisional application (Rule 68(4) EPC).

(71) Applicant: **The Rockefeller University**
New York, NY 10021-6399 (US)

(72) Inventors:
• **RAVETCH, Jeffrey V.**
New York, NY 10022 (US)

(54) **POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS**

(57) The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.

EP 3 456 351 A1

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to United States Provisional Patent Application Serial No. 60/789,384 filed on April 5, 2006.

STATEMENT REGARDING FEDERALLY FUNDED RESEARCH

[0002] The Research leading to the present invention was supported in part, by National Institutes of Health Grant No. AI 034662. Accordingly, the U.S. Government may have certain rights in this invention.

FIELD OF THE INVENTION

[0003] The present invention relates to novel methods for designing therapeutic polypeptides for treatment of inflammatory diseases.

BACKGROUND OF THE INVENTION

[0004] Although cellular receptors for immunoglobulins were first identified nearly 40 years ago, their central role in the immune response was only discovered in the last decade. They are key players in both the afferent and efferent phase of an immune response, setting thresholds for B cell activation and antibody production, regulating the maturation of dendritic cells and coupling the exquisite specificity of the antibody response to effector pathways, such as phagocytosis, antibody dependent cellular cytotoxicity and the recruitment and activation of inflammatory cells. Their central role in linking the humoral immune system to innate effector cells has made them attractive immunotherapeutic targets for either enhancing or restricting the activity of antibodies *in vivo*.

[0005] The interaction of antibodies and antibody-antigen complexes with cells of the immune system effects a variety of responses, including antibody dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC), phagocytosis, inflammatory mediator release, clearance of antigen, and antibody half-life (reviewed in Daron, *Annu Rev Immunol*, 15, 203-234 (1997); Ward and Ghetie, *Therapeutic Immunol*, 2, 77-94 (1995); Ravetch and Kinet, *Annu Rev Immunol*, 9, 457-492 (1991)), each of which is incorporated herein by reference).

[0006] Antibody constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions. Depending on the amino acid sequence of the constant region of their heavy chains, antibodies or immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g.,

IgG1, IgG2, IgG3, and IgG4; IgA1 and IgA2. The heavy chain constant regions that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively. Of the various human immunoglobulin classes, human IgG1 and IgG3 mediate ADCC more effectively than IgG2 and IgG4.

[0007] Papain digestion of antibodies produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. The Fc region is central to the effector functions of antibodies. The crystal structure of the human IgG Fc region has been determined (Deisenhofer, *Biochemistry*, 20, 2361-2370 (1981), which is incorporated herein by reference). In human IgG molecules, the Fc region is generated by papain cleavage N-terminal to Cys, 226.

[0008] IgG has long been appreciated to mediate both pro- and anti-inflammatory activities through interactions mediated by its Fc fragment. Thus, while Fc-Fc γ R interactions are responsible for the pro-inflammatory properties of immune complexes and cytotoxic antibodies, intravenous gamma globulin (IVIG) and its Fc fragments are anti-inflammatory and are widely used to suppress inflammatory diseases. The precise mechanism of such paradoxical properties is unclear but it has been proposed that glycosylation of IgG is crucial for regulation of cytotoxicity and inflammatory potential of IgG.

[0009] IgG contains a single, N-linked glycan at Asn²⁹⁷ in the CH2 domain on each of its two heavy chains. The covalently-linked, complex carbohydrate is composed of a core, biantennary penta-polysaccharide containing N-acetylglucosamine (GlcNAc) and mannose (man). Further modification of the core carbohydrate structure is observed in serum antibodies with the presence of fucose, branching GlcNAc, galactose (gal) and terminal sialic acid (sa) moieties variably found. Over 40 different glycoforms have thus been detected to be covalently attached to this single glycosylation site. Fujii et al., *J. Biol. Chem* 265, 6009 (1990). Glycosylation of IgG has been shown to be essential for binding to all Fc γ Rs by maintaining an open conformation of the two heavy chains. Jefferis and Lund, *Immune-1 Lett.* 82, 57 (2002), Sondermann et al., *J. Mol. Biol.* 309, 737 (2001). This absolute requirement of IgG glycosylation for Fc γ R binding accounts for the inability of deglycosylated IgG antibodies to mediate *in vivo* triggered inflammatory responses, such as ADCC, phagocytosis and the release of inflammatory mediators. Nimmerjahn and Ravetch, *Immunity* 24, 19 (2006). Further observations that individual glycoforms of IgG may contribute to modulating inflammatory responses have been suggested by the altered affinities for individual Fc γ Rs reported for IgG antibodies containing or lacking fucose and their consequential affects on cytotoxicity. Shields et al., *J. Biol. Chem.* 277, 26733 (2002), Nimmerjahn and Ravetch, *Science* 310, 1510 (2005). A link between autoimmune states and specific glycosylation patterns of IgG antibodies has been

observed in patients with rheumatoid arthritis and several autoimmune vasculitides in which decreased galactosylation and sialylation of IgG antibodies have been reported. Parekh et al., *Nature* 316, 452 (1985), Rademacher et al., *Proc. Natl. Acad. Sci. USA* 91, 6123 (1994), Matsumoto et al., 128, 621 (2000), Holland et al., *Biochim. Biophys. Acta* Dec 27; [Epub ahead of print] 2005. Variations in IgG glycoforms have also been reported to be associated with aging and upon immunization, although the *in vivo* significance of these alterations have not been determined. Shikata et al., *Glycoconj. J.* 15, 683 (1998), Lastra, et al., *Autoimmunity* 28, 25 (1998).

[0010] Accordingly, there is a need for the development of methods for the generation of polypeptides that would account for the disparate observations of IgG properties *in vivo*.

SUMMARY OF THE INVENTION

[0011] The present invention fills the foregoing need by providing such methods and molecules. In one aspect, the invention provides a polypeptide containing at least one IgG Fc region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody. In different embodiments of the invention, the polypeptide comprises a human IgG1, IgG2, IgG3 or IgG4 Fc region, said polypeptide having a higher sialic acid content as compared to an unpurified antibody.

[0012] In another aspect, the instant invention provides a pharmaceutical formulation comprising a polypeptide containing at least one Fc region having a higher anti-inflammatory activity and a lower cytotoxic activity, in combination with a suitable carrier or diluent.

[0013] In yet another aspect, the invention provides a method of preparation of a polypeptide containing at least one Fc region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity than an unpurified antibody, the method comprising: providing an unpurified source of the polypeptide containing at least one Fc region, the unpurified source of the polypeptide containing at least one Fc region comprising a plurality of polypeptides containing at least one IgG Fc region having sialic acid and a plurality of polypeptides containing at least one IgG Fc region lacking sialic acid; and increasing the ratio of the plurality of the polypeptides containing at least one IgG Fc region having sialic acid to the plurality of the polypeptides containing at least one IgG Fc region lacking sialic acid. In different embodiments of the invention, the ratio of the plurality of the polypeptides containing at least one IgG Fc region having sialic acid to the plurality of the polypeptides containing at least one IgG Fc region lacking sialic acid is achieved either through a removal of the polypeptides containing at least one IgG Fc region lacking sialic acid or through a sialylation of the unpurified source the of polypeptides containing at least one IgG Fc region.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014]

5 Figure 1 demonstrates carbohydrate spectra of 6A6-IgG antibody isotypes. N-glycans derived from 6A6-IgG1, IgG2a and IgG2b were analyzed by MALDI-TOF MS. Peaks containing sialic acid residues are indicated by the bracket. Recombinant 6A6 antibody switch variants produced by transient transfection of 293T cells contained minimal levels of sialic acid residues in their Asn-297 attached carbohydrates.

10 Figure 2 shows that sialylation reduces IgG cytotoxicity. (A) Structure of the fully processed carbohydrate moiety attached to asparagine 297 (N297) in the antibody Fc-fragment. The core sugar structure is shown in bold. Variable residues such as the terminal and bisecting sugars are underlined and specific linkages are indicated. Cleavage sites for PNGase and neuraminidase are also indicated. This fully processed structure is present in about 5% of the total serum IgG pool (1). Abbreviations: GlcNAc=N-acetyl glucosamine, man= mannose, gal=galactose, sa=sialic acid. (B) Enrichment of 6A6-IgG1 and IgG2b antibodies with high sialic acid content via *Sambucus nigra* agglutinin (SNA) affinity chromatography. (C) *In vivo* activity of 6A6-IgG1 and -IgG2b antibodies enriched for sialic acid (SA) or depleted for sialic acid by neuraminidase (NA) treatment. 4 μ g of each antibody' was injected into groups of mice (N=4, mean \pm SEM); * indicates $p < 0.0001$, ** indicates $p < 0.01$. (D) Association constants (K_A) for Fc γ R1IB, Fc γ R1II and Fc γ R1IV in binding to antibodies with high or low levels of sialylation; n.b. indicates no binding. Bold numbers indicate the isotype specific Fc-receptors that are responsible for mediating antibody activity *in vivo*. The standard error in all these measurements was below 5 %.

30 Figure 3 illustrates that antibody activity *in vivo* is modulated by sialic acid. 6A6-IgG1 was enriched for sialic acid by affinity chromatography with SNA-agarose. A fraction of this SNA-enriched preparation was treated with neuraminidase (SNA-enriched + Neuraminidase). (A) Sialic acid content in antibody preparations was determined by lectin blotting with SNA. (B) *In vivo* antibody activity was tested by monitoring platelet depletion induced by injection of 4 μ g of the respective antibody preparations (n=4-5 mice per group).

40 Figure 4 demonstrates that anti-inflammatory activity of IVIG requires sialic acid. (A) Clinical scores of K/BxN serum-induced arthritis in mice treated with PBS, IVIG, and PNGaseF-treated IVIG (PNGaseF IVIG). (B) In addition to treatment as shown in Fig. 4(A), mice were treated with neuraminidase-treated IVIG (NA IVIG) or SNA-enriched IVIG (SNA IVIG). (C) Clinical scores of mice treated with Fc fragment of IVIG, neuraminidase-treated Fc (NA Fc), or SNA-

enriched Fc (SNA Fc) (N=4, mean +/- SEM). (D) Carbohydrate profiles of IVIG preparations. MALDI-TOF-MS profiles of N-glycans derived from untreated or neuraminidase-treated IVIG are shown. Peaks that contain sialic acid residues are indicated by a bracket and the carbohydrate composition of the peaks are presented in Fig. 5. (E) Representative hematoxylin/eosin staining of ankle joints of control mice or K/N induced arthritis mice treated with or without SNA-enriched IVIG (0.1 g/kg). The extensive neutrophil infiltration observed in K/N treated mice is absent from IVIG-SNA (0.1g/kg) treated mice. (F) Lectin blotting of control Fc fragment of IVIG, neuraminidase-treated Fc (NA Fc) and Fc with high sialic acid content via *Sambucus nigra* agglutinin (SNA) affinity chromatography (SNA Fc). (G) Analysis of 2,3 and 2,6 linked sialic acid residues in IVIG. IVIG was either left untreated (lane2) or treated with a neuraminidase specific for 2,3 linked sialic acid residues (lane3) or a neuraminidase specific for 2,3 and 2,6 linked sialic acid residues (lane 4). Removal of sialic acid was assayed by lectin blotting with SNA (which recognizes 2,6 linked sialic acid residues) and MAL-I (which recognizes 2,3 linked sialic acid residues). As a control for a glycoprotein rich in 2,3 linked sialic acid residues fetuin was used (lane 1). The coomassie stained gel served as a loading control (Coomassie). (H) Anti-inflammatory activity of IVIG depleted in 2,3 or 2,3 and 2,6 linked sialic acid residues. Mice were injected with KRN serum to induce arthritis and either left untreated (KRN), treated with IVIG (KRN +IVIG), IVIG-depleted in 2,3 linked sialic acid residues (α 2-3 sialidase tx IVIG +KRN), or IVIG depleted in 2,3 and 2,6 linked sialic acid residues (α 2-3,6 sialidase tx IVIG +KRN). As a negative control mice were injected with PBS (untreated).

Figure 5 illustrates the composition of the carbohydrate moieties released from N297 IgG Fc. The core sugar structure linked to the asparagine residue 297 in the antibody heavy chain is composed of N-acetylglucosamine (GlcNAc) and mannose (Man). Individual glycoforms vary with respect to attachment of one or two terminal galactose (Gal) residues, attachment of terminal sialic acid. (N-acetylneuraminic acid or Neu5Ac for human and N-glycolylneuraminic acid or Neu5Gc for mouse) residues, and/or the attachment of bisecting GlcNAc or fucose (Fuc). Numbers indicate the molecular weight of the different sugar compositions as determined by MALDI-TOF MS. The mass for the glycan structures are indicated for human and mouse (underlined).

Figure 6 illustrates serum half-life and protein integrity of de-sialylated IVIG. (A) The level of human IgG in the serum of IVIG treated mice on the indicated days was measured by ELISA (N = 4, mean +/- SEM). There was no significant difference in half-life of IVIG and de-sialylated IVIG. Significance was determined by the repeated measure ANOVA-test. (B)

Ten microgram of IVIG or de-sialylated IVIG were resolved by SDS-PAGE using an 8% polyacrylamide gel under non-reduced conditions and visualized with coomassie brilliant blue staining. The monomeric composition and structural integrity of IVIG were not affected by neuraminidase treatment.

Figure 7 demonstrates serum half-life and subclass composition of SNA-enriched IVIG. (A) The level of human IgG in the serum of IVIG treated mice at the indicated days was measured by ELISA (N = 4, mean +/- SEM). There was no significant difference in half-life of IVIG and the SNA-enriched IVIG fraction. Significance was determined by the repeated measure ANOVA test. (B) IgG subclasses in untreated and SNA-enriched IVIG were determined by ELISA. No differences were observed.

Figure 8 illustrates that sialylated proteins with similar carbohydrate structures do not protect mice from K/BxN serum induced arthritis. Equivalent molar amounts (6.7 μ .mol per kilogram) or equal weight (1 g per kilogram) of IVIG or sialo-proteins fetuin and transferrin were administered 1 hr before K/BxN serum injection, and clinical scores were examined on day 4 (N = 4, mean +/- SEM). PBS was used as an additional control. Compared to IgG, fetuin or transferrin had no statistically significant anti-inflammatory activity at equivalent molar concentrations. Significance was calculated with the Mann-Whitney's U test.

Figure 9 demonstrates that anti-inflammatory activity of SNA enriched IVIG requires Fc γ RIIB. (A) Unfractionated IVIG (1 g/kg mouse weight), SNA-enriched IVIG (0.1 g/kg mouse weight), or PBS as a control were injected into Fc γ RIIB-deficient mice 1 hr before K/BxN serum injection, and clinical scores were examined on day 4 (N = 4, mean +/-SEM). There were no significant differences in clinical scores of arthritis. Significance was calculated with the Mann-Whitney's U test. (B) *In vivo* accumulation of Fc γ RIIB⁺ monocytes by SNA-enriched IVIG. Wild type mice were injected with 1 g/kg, 0.1 g/kg IVIG or 0.1 g/kg of SNA-enriched IVIG, or PBS as a control. Bone marrow (left panel) and spleen cells (right panel) were collected and analyzed by flow cytometry 1 day after the injection (N = 4). F4/80⁺ Fc γ RIIB⁺ cells accumulated significantly after treatment with 1 g/kg of IVIG or 0.1 g/kg of SNA-enriched IVIG. Significance was calculated with the Student's t test.

Figure 10 demonstrates that active immunization results in reduced IgG sialylation. (A) Serum IgG from untreated (preimmune) or mice with nephrotic nephritis (NTN) induced by immunization with sheep IgG and nephrotoxic serum (NTS) was characterized for sialic acid content by blotting with *Sambucus nigra agglutinin* (SNA) (see methods). (B) Quantitation of the level of sialylation of total serum IgG and IgM antibodies and sheep IgG-specific IgG antibodies in untreated and NTN mice (mean +/- SEM) as deter-

mined by densitometry. No detectable sheep IgG was present in the mouse antibody preparations (data not shown). (C) MALDI-TOF analysis of sugar residues attached to IgG antibodies from untreated or NTN mice. Sialic acid containing moieties are indicated by a bracket. The detailed carbohydrate composition of the individual peaks is shown in Fig. 5. (D) Detection of sialic acid content in antibodies deposited in the glomeruli of mice injected with nephrotoxic serum with (NTS+CFA) or without (NTS alone) preimmunization with sheep IgG in complete Freund's adjuvant (CFA).

DETAILED DESCRIPTION OF THE INVENTION

[0015] The inventors have surprisingly found that the cytotoxic and anti-inflammatory response of the IgG Fc domain results from the differential sialylation of the Fc-linked core polysaccharide. The cytotoxicity of IgG antibodies is reduced upon sialylation; conversely, the anti-inflammatory activity of IVIG is enhanced. IgG sialylation is shown to be regulated upon the induction of an antigen-specific immune response, thus providing a novel means of switching IgG from an innate, anti-inflammatory molecule in the steady-state, to a adaptive, pro-inflammatory species upon antigenic challenge.

[0016] Accordingly, the instant disclosure provides an advantageous strategy of creating and selecting IgGs with desired cytotoxic and anti-inflammatory potential.

DEFINITIONS

[0017] Throughout the present specification and claims, the numbering of the residues in an immunoglobulin heavy chain is that of the EU index as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), which is expressly incorporated herein by reference. The "EU index as in Kabat" refers to the residue numbering of the human IgG1 EU antibody.

[0018] The term "native" or "parent" refers to an unmodified polypeptide comprising an Fc amino acid sequence. The parent polypeptide may comprise a native sequence Fc region or an Fc region with pre-existing amino acid sequence modifications (such as additions, deletions and/or substitutions).

[0019] The term "polypeptide" refers to any fragment of a protein containing at least one IgG Fc region, including, without limitation, fully functional proteins, such as, for example, antibodies, e.g., IgG antibodies.

[0020] The term "Fc region" is used to define a C-terminal region of an immunoglobulin heavy chain. The "Fc region" may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof.

[0021] The "CH2 domain" of a human IgG Fc region (also referred to as "C γ 2" domain) usually extends from about amino acid 231 to about amino acid 340. The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG molecule. It has been speculated that the carbohydrate may provide a substitute for the domain-domain pairing and help stabilize the CH2 domain (Burton, Mol Immunol, 22, 161-206 (1985), which is incorporated herein by reference).

[0022] The "CH3 domain" comprises the stretch of residues C-terminal to a CH2 domain in an Fc region (i.e., from about amino acid residue 341 to about amino acid residue 447 of an IgG).

[0023] The term "hinge region" is generally defined as stretching from Glu216 to Pro230 of human IgG1 (Burton (1985). Hinge regions of other IgG isotypes may be aligned with the IgG1 sequence by placing the first and last cysteine residues forming inter-heavy chain S-S bonds in the same positions.

[0024] The term "binding domain" refers to the region of a polypeptide that binds to another molecule. In the case of an FcR, the binding domain can comprise a portion of a polypeptide chain thereof (e.g., the α chain thereof) which is responsible for binding an Fc region. One exemplary binding domain is the extracellular domain of an FcR chain.

[0025] A "functional Fc region" possesses at least a partial "effector function" of a native sequence Fc region. Exemplary "effector functions" include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc. Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an antibody variable domain) and can be assessed using various assays as herein disclosed, for example.

[0026] A "native sequence Fc region" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. A "variant Fc region" as appreciated by one of ordinary skill in the art comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one "amino acid modification." Preferably, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g., from about one to about ten amino acid substitutions, and preferably from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent polypeptide. The variant Fc region herein will preferably possess at least about 80% homology with a native sequence Fc region and/or with an Fc region of a parent polypeptide, and more preferably at least about 90% homology therewith, more preferably at least about 95% homology therewith, even more preferably, at least about 99% homology

therewith.

[0027] The term "altered glycosylation" refers to a polypeptide, as defined above, be it native or modified, in which the carbohydrate addition to the heavy chain constant region is manipulated to either increase or decrease specific sugar components. For example, polypeptides, such as, for example, antibodies, prepared in specific cell lines, such as, for example, Lec2 or Lec3, may be deficient in the attachment of sugar moieties such as fucose and sialic acid.

[0028] The terms "Fc receptor" or "FcR" are used to describe a receptor that binds to the Fc region of an antibody. In one embodiment of the invention, FcR is a native sequence human FcR. In another embodiment, FcR, including human FcR, binds an IgG antibody (a gamma receptor) and includes receptors of the Fc γ RI, Fc γ RII, and Fc γ RIII subclasses, including allelic variants and alternatively spliced forms of these receptors. Fc γ RII receptors include Fc γ RIIA (an "activating receptor") and Fc γ RIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor Fc γ RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor Fc γ RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (see review in Daron, *Annu Rev Immunol*, 15, 203-234 (1997); FcRs are reviewed in Ravetch and Kinetic, *Annu Rev Immunol*, 9, 457-92 (1991); Capel et al., *Immunomethods*, 4, 25-34 (1994); and de Haas et al., *J Lab Clin Med*, 126, 330-41 (1995), Nimmerjahn and Ravetch 2006, *Ravetch Fc Receptors in Fundamental Immunology*, ed William Paul 5th Ed. each of which is incorporated herein by reference).

"Antibody-dependent cell-mediated cytotoxicity" and "ADCC" refer to an in vitro or in vivo cell-mediated reaction in which cytotoxic cells that express FcRs (e.g., monocytic cells such as natural killer (NK) cells and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. In principle, any effector cell with an activating Fc γ R can be triggered to mediate ADCC. One such cell, the NK cell, expresses Fc γ RIII only, whereas monocytes, depending on their state of activation, localization, or differentiation, can express Fc γ RI, Fc γ RII, and Fc γ RIII. FcR expression on hematopoietic cells is summarized in Ravetch and Bolland, *Annu Rev Immunol*, (2001), which is incorporated herein by reference.

"Human effector cells" are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least one type of an activating Fc receptor, such as, for example, Fc γ RIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, and neutrophils, with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source thereof, e.g., from blood or PBMCs as described

herein.

[0029] The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.

[0030] The phrase "sialic acid content" of an antibody refers both to the total number of sialic acid residues on an Fc region of a heavy chain of an antibody and to the ratio of sialylated antibodies to asialylated antibodies in an unpurified antibody preparation, unless the phrase is in a context clearly suggesting that another meaning is intended.

"Antibody fragments", as defined for the purpose of the present invention, comprise a portion of an intact antibody, generally including the antigen binding or variable region of the intact antibody or the Fc region of an antibody which retains FcR binding capability. Examples of antibody fragments include linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. The antibody fragments preferably retain at least part of the hinge and optionally the CH1 region of an IgG heavy chain. More preferably, the antibody fragments retain the entire constant region of an IgG heavy chain, and include an IgG light chain.

[0031] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler and Milstein, *Nature*, 256, 495-497 (1975), which is incorporated herein by reference, or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567, which is incorporated herein by reference). The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al., *Nature*, 352, 624-628 (1991) and Marks et al., *J Mol Biol*, 222, 581-597 (1991), for example, each of which is incorporated herein by reference.

[0032] In other embodiments of the invention, the polypeptide containing at least one IgG Fc region may be fused with other protein fragments, including, without limitation, whole proteins. A person of ordinary skill in the

art will undoubtedly appreciate that many proteins may be fused with the polypeptide of the present invention, including, without limitation, other immunoglobulins, especially, immunoglobulins lacking their respective Fc regions. Alternatively, other biologically active proteins or fragments thereof may be fused with the polypeptide of the present invention, as described, for example, in the U.S. Patent No. 6,660,843, which is incorporated herein by reference. This embodiment is especially advantageous for delivery of such biologically active proteins or fragments thereof to cells expressing Fc receptors. Further, different markers, such as, for example, GST tag or green fluorescent protein, or GFP, may be used.

[0033] The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U.S. Patent No. 4,816,567; Morrison et al., Proc Natl Acad Sci USA, 81, 6851-6855 (1984); Neuberger et al., Nature, 312, 604-608 (1984); Takeda et al., Nature, 314, 452-454 (1985); International Patent Application No. PCT/GB85/00392, each of which is incorporated herein by reference).

[0034] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR residues are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321, 522-525 (1986); Riechmann et al., Nature, 332, 323-329 (1988); Presta, Curr Op Struct Biol, 2, 593-596 (1992); U.S. Patent No. 5,225,539, each of which is in-

corporated herein by reference.

[0035] The polypeptides containing at least one IgG Fc region include those in which specific amino acid substitutions, additions or deletions are introduced into a parental sequence through the use of recombinant DNA techniques to modify the genes encoding the heavy chain constant region. The introduction of these modifications follows well-established techniques of molecular biology, as described in manuals such as Molecular Cloning (Sambrook and Russel, (2001)). In addition, the polypeptides with at least one Fc region will include those polypeptides which have been selected to contain specific carbohydrate modifications, obtained either by expression in cell lines known for their glycosylation specificity (Stanley P., et al., Glycobiology, 6, 695-9 (1996); Weikert S., et al., Nature Biotechnology, 17, 1116-1121 (1999); Andresen DC and Krummen L., Current Opinion in Biotechnology, 13, 117-123 (2002)) or by enrichment or depletion on specific lectins or by enzymatic treatment (Hirabayashi et al., J Chromatogr B Analyt Technol Biomed Life Sci, 771, 67-87 (2002); Robertson and Kennedy, Bioseparation, 6, 1-15 (1996)). It is known in the art that quality and extent of antibody glycosylation will differ depending on the cell type and culture condition employed. (For example, Patel et al., Biochem J, 285, 839-845 (1992)) have reported that the content of sialic acid in antibody linked sugar side chains differs significantly if antibodies were produced as ascites or in serum-free or serum containing culture media. Moreover, Kunkel et al., Biotechnol Prog, 16, 462-470 (2000) have shown that the use of different bioreactors for cell growth and the amount of dissolved oxygen in the medium influenced the amount of galactose and sialic acid in antibody linked sugar moieties. These studies, however, did not address how varying levels of sialic acid residues influence antibody activity in vivo.

Host Expression Systems

[0036] The polypeptide of the present invention can be expressed in a host expression system, i.e., host cells, capable of N-linked glycosylation. Typically, such host expression systems may comprise fungal, plant, vertebrate or invertebrate expression systems. In one embodiment the host cell is a mammalian cell, such as a Chinese hamster ovary (CHO) cell line, (e.g. CHO-K1; ATCC CCL-61), Green Monkey cell line (COS) (e.g. COS 1 (ATCC CRL-1650), COS 7 (ATCC CRL-1651)); mouse cell (e.g. NS/0), Baby Hamster Kidney (BHK) cell line (e.g. ATCC CRL-1632 or ATCC CCL-10), or human cell (e.g. HEK 293 (ATCC CRL-1573)), or any other suitable cell line, e.g., available from public depositories such as the American Type Culture Collection, Rockville, Md. Further, an insect cell line, such as a Lepidoptera cell line, e.g. Sf9, a plant cell line, a fungal cell line, e.g., yeast such as, for example, Saccharomyces cerevisiae, Pichia pastoris, Hansenula spp. It will be appreciated by one of ordinary skill in the art that in some cases modifications

to host cells may be required to insure that N-linked glycosylation and glycan maturation occur to result in a complex, biantennary sugar as typically found on the Fc domain of human IgG (see for example Hamilton, SR, et al. Science, 313,1441 (2006); Li, H, et al., Nature Biotechnology 24, 210 (2006); Wildt,S and Grengross, TU Nature Reviews Microbiology 3, 119 (2005)..

Therapeutic Formulations

[0037] Therapeutic formulations comprising the polypeptides containing at least one IgG Fc region can be prepared for storage by mixing the polypeptides of the present invention having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (see, e.g., Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyl-dimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenyl, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).

[0038] The formulations herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

[0039] The active ingredients may also be entrapped in a microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacrylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0040] In preferred embodiments, the formulations to be used for *in vivo* administration are sterile. The formu-

lations of the instant invention can be easily sterilized, for example, by filtration through sterile filtration membranes.

[0041] Sustained-release preparations may also be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the modified antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (see, e.g., U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

[0042] Creation of sialylated polypeptides containing at least one IgG Fc region.

[0043] The polypeptides of the present invention can be further purified or modified so that they have an increased amount of sialic acid compared to unmodified and/or unpurified antibodies. Multiple methods exist to reach this objective. In one method, the source of unpurified polypeptides, such as, for example, plasma fractions that contain IgG from which IVIG is routinely purified, is passed through the column having lectin, which is known to bind sialic acid. In one embodiment, the lectin is isolated from *Sambucus nigra*. Thus, a sialylated fraction of the polypeptides containing at least one IgG Fc region will be retained in the column while an asialylated fraction will pass through. The sialylated fraction of the polypeptides containing at least one IgG Fc region can be eluted by another wash with a different stringency conditions. Thus, it is possible to obtain a preparation of the polypeptide of the present invention wherein the content of sialic acid is increased compared to the normal content. Further, one may employ an enzymatic reaction with a sialyltransferase and a donor of sialic acid as described, for example, in the U.S. Pat. No. 20060030521.

[0044] Suitable non-limiting examples of sialyltransferase enzymes useful in the claimed methods are

ST3Gal III, which is also referred to as α -(2,3)sialyltransferase (EC 2.4.99.6), and α -(2,6)sialyltransferase (EC 2.4.99.1). Alpha-(2,3)sialyltransferase catalyzes the transfer of sialic acid to the Gal of a Gal- β -1,3GlcNAc or Gal- β -1,4GlcNAc glycoside (see, e.g., Wen et al., J. Biol. Chem. 267: 21011 (1992); Van den Eijnden et al., J. Biol. Chem. 256: 3159 (1991)) and is responsible for sialylation of asparagine-linked oligosaccharides in glycopeptides. The sialic acid is linked to a Gal with the formation of an α -linkage between the two saccharides. Bonding (linkage) between the saccharides is between the 2-position of NeuAc and the 3-position of Gal. This particular enzyme can be isolated from rat liver (Weinstein et al., J. Biol. Chem. 257: 13845 (1982)); the human cDNA (Sasaki et al. (1993) J. Biol. Chem. 268: 22782-22787; Kitagawa & Paulson (1994) J. Biol. Chem. 269: 1394-1401) and genomic (Kitagawa et al. (1996) J. Biol. Chem. 271: 931-938) DNA sequences are known, facilitating production of this enzyme by recombinant expression.

[0045] Activity of α -(2,6)sialyltransferase results in 6-sialylated oligosaccharides, including 6-sialylated galactose. The name " α -(2,6)sialyltransferase" refers to the family of sialyltransferases attaching sialic acid to the sixth atom of the acceptor polysaccharide. Different forms of α -(2,6)sialyltransferase can be isolated from different tissues. For example, one specific form of this enzyme, ST6Gal II, can be isolated from brain and fetal tissues. Krzewinski-Recchi et al., Eur. J. Biochem. 270, 950 (2003).

[0046] In addition, a person of average skill in the art will appreciate that cell culture conditions can be manipulated to change the sialylation rate. For example, to increase the sialic acid content, production rate is decreased and osmolality is generally maintained within a lower margin suitable for the particular host cell being cultured. Osmolality in the range from about 250 mOsm to about 450 mOsm is appropriate for increased sialic acid content. This and other suitable cell culture conditions are described in, e.g., U.S. Patent No. 6,656,466. Patel et al., Biochem J, 285, 839-845 (1992) have reported that the content of sialic acid in antibody linked sugar side chains differs significantly if antibodies were produced as ascites or in serum-free or serum containing culture media. Moreover, Kunkel et al., Biotechnol. Prog., 16, 462-470 (2000) have shown that the use of different bioreactors for cell growth and the amount of dissolved oxygen in the medium influenced the amount of galactose and sialic acid in antibody linked sugar moieties.

[0047] In another embodiment, host cells, such as, for example, immortalized human embryonic retina cells, may be modified by introducing a nucleic acid encoding a sialyltransferase such as, for example, an α -2,3-sialyltransferase or an α -2,6-sialyltransferase, operably linked to a promoter, such as, for example, a CMV promoter. The α -2,3-sialyltransferase may be the human α -2,3-sialyltransferase, known as SIAT4C or STZ (GenBank accession number L23767), and described, for example, in the U.S. Pat. No. 20050181359.

[0048] The nucleic acid encoding the sialyltransferase may be introduced into the host cell by any method known to a person of ordinary skill in the art. Suitable methods of introducing exogenous nucleic acid sequences are also described in Sambrook and Russel, Molecular Cloning: A Laboratory Manual (3rd Edition), Cold Spring Harbor Press, NY, 2000. These methods include, without limitation, physical transfer techniques, such as, for example, microinjection or electroporation; transfections, such as, for example, calcium phosphate transfections; membrane fusion transfer, using, for example, liposomes; and viral transfer, such as, for example, the transfer using DNA or retroviral vectors.

[0049] The polypeptide containing at least one IgG Fc region may be recovered from the culture supernatant and can be subjected to one or more purification steps, such as, for example, ion-exchange or affinity chromatography, if desired. Suitable methods of purification will be apparent to a person of ordinary skill in the art.

[0050] A person of ordinary skill in the art will appreciate that different combinations of sialylation methods, disclosed above, can lead to production of the polypeptides containing at least one IgG Fc region with an extremely high level of sialylation. For example, one can express the polypeptide containing at least one IgG Fc region in the host cells overexpressing sialyltransferase, as described above, and then further enrich the sialylated fraction of these polypeptides by, for example, sialylating these polypeptides in an enzymatic reaction followed by an affinity chromatography using lectin-containing columns. Similarly, an enzymatic reaction followed by affinity chromatography may be used for IVIG source of the polypeptides containing at least one IgG Fc region.

[0051] To examine the extent of glycosylation on the polypeptides containing at least one IgG Fc region, these polypeptides can be purified and analyzed in SDS-PAGE under reducing conditions. The glycosylation can be determined by reacting the isolated polypeptides with specific lectins, or, alternatively as would be appreciated by one of ordinary skill in the art, one can use HPLC followed by mass spectrometry to identify the glycoforms. (Wormald, MR et al., Biochem 36:1370 (1997).

[0052] To describe the instant invention in more details, several non-limiting illustrative examples are given below.

EXAMPLES

EXAMPLE 1. IVIG WITH INCREASED SIALIC ACID CONTENT EXHIBITS DECREASED CYTOTOXICITY

[0053] To determine if specific glycoforms of IgG are involved in modulating the effector functions of antibodies the role of specific, Asn²⁹⁷ - linked carbohydrates in mediating the cytotoxicity of defined IgG monoclonal antibodies was explored. The anti-platelet antibodies, derived from the 6A6 hybridoma, expressed as either an IgG1, 2a or 2b switch variant in 293 cells as previously

described in Nimmerjahn et al., *Immunity* 23, 41 (2005) were analyzed by mass spectroscopy to determine their specific carbohydrate composition and structure (Figure 1). These antibodies contain minimal sialic acid residues. Enrichment of the sialic acid containing species by *Sambucus nigra* lectin affinity chromatography yielded antibodies enriched 60-80 fold in sialic acid content (Figure 2B and Figure 3). Comparison of the ability of sialylated and asialylated 6A6-IgG1 and 2b antibodies to mediate platelet clearance revealed an inverse correlation between sialylation and in vivo activity. Sialylation of 6A6 IgG antibodies resulted in a 40-80% reduction in biological activity (Figure 2C and Figure 3).

[0054] To determine the mechanism of this reduction in activity surface plasmon resonance binding was performed on these antibodies for each of the mouse FcYRs and to its cognate antigen.

[0055] Surface plasmon resonance analysis was performed as described in Nimmerjahn and Ravetch, *Science* 310, 1510 (2005). Briefly, 6A6 antibody variants containing high or low levels of sialic acid residues in their sugar side chains were immobilized on the surface of CM5 sensor chips. Soluble Fcy-receptors were injected at different concentrations through flow cells at room temperature in HBS-EP running buffer (10mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% surfactant P20) at a flow rate of 30 ul/min. Soluble Fc-receptors were injected for 3 minutes and dissociation of bound molecules was observed for 7 minutes. Background binding to control flow cells was subtracted automatically. Control experiments were performed to exclude mass transport limitations. Affinity constants were derived from sensorgram data using simultaneous fitting to the association and dissociation phases and global fitting to all curves in the set. A 1:1 Langmuir binding model closely fitted the observed sensorgram data and was used in all experiments.

[0056] A 5-10 fold reduction in binding affinity was observed for the sialylated forms of these antibodies to their respective activating FcyRs as compared to their asialylated counterparts, while no differences in binding affinity for the antigen were observed (Figure 2D). Thus, sialylation of the Asn²⁹⁷ linked glycan structure of IgG resulted in reduced binding affinities to the subclass-restricted activation FcyRs and thus reduced their in vivo cytotoxicity.

[0057] To determine the generality of the observation that sialylation of the N-linked glycan of IgG was involved in modulating its in vivo inflammatory activity, we next examined the role of N-linked glycans on the anti-inflammatory activity of IVIG. This purified IgG fraction obtained from the pooled serum of 5-10,000 donors, when administered intravenously at high doses (1-2 g/kg), is a widely used therapeutic for the treatment of inflammatory diseases. Dwyer, *N. Engl. J. Med.* 326, 107 (1992). This anti-inflammatory activity is a property of the Fc fragment and is protective in murine models of ITP, RA and nephrotic nephritis. Imbach et al., *Lancet* 1, 1228 (1981),

Samuelsson et al., *Science* 291, 484 (2001), Bruhns et al., *Immunity* 18, 573 (2003), Kaneko et al., *J. Exp. Med.* 203, 789 (2006)

[0058] A common mechanism for this anti-inflammatory activity was proposed involving the induction of surface expression of the inhibitory FcyRIIB molecule on effector macrophages, thereby raising the threshold required for cytotoxic IgG antibodies or immune complexes to induce effector cell responses by activation FcyR triggering. Nimmerjahn and Ravetch, *Immunity* 24, 19 (2006).

EXAMPLE 2. DE-SIALYLATION OF IVIG DECREASES THE ANTI-INFLAMMATORY EFFECT OF IVIG IN MOUSE ARTHRITIS MODEL

Mice

[0059] C57BL/6 and NOD mice were purchased from the Jackson Laboratory (Bar Harbor, ME). FcyRIIB^{-/-} mice were generated in the inventors' laboratory and backcrossed for 12 generations to the C57BL/6 background. KRN TCR transgenic mice on a C57BL/6 background (K/B) were gifts from D. Mathis and C. Benoist (Harvard Medical School, Boston, MA) and were bred to NOD mice to generate K/BxN mice. Female mice at 8-10 weeks of age were used for all experiments and maintained at the Rockefeller University animal facility. All experiments were done in compliance with federal laws and institutional guidelines and have been approved by the Rockefeller University (New York, NY).

Antibodies and soluble Fc receptors

[0060] 6A6 antibody switch variants were produced by transient transfection of 293T cells followed by purification via protein G as described in Nimmerjahn et al., *Immunity* 23, 41 (2005) and Nimmerjahn and Ravetch, *Science* 310, 1510 (2005). Sialic acid rich antibody variants were isolated from these antibody preparations by lectin affinity chromatography with *Sambucus nigra* agglutinin (SNA) agarose (Vector Laboratories, Burlingame, CA). Enrichment for sialic acid content was verified by lectin blotting (see below). Human intravenous immune globulin (IVIG, 5% in 10% maltose, chromatography purified) was purchased from Octapharma (Hemdon, VA). Digestion of human IVIG was performed as described. Kaneko Y. et al., *Exp. Med.* 203,789 (2006). Briefly, IVIG was digested by 0.5 mg/ml papain for 1 hr at 37 °C, and stopped by the addition of 2.5 mg/ml iodoacetamide. Fab and Fc resulting fragments were separated from non-digested IVIG on a HiPrep 26/60 S-200HR column (GE Healthcare, Piscataway, NJ), followed by purification of Fc and Fab fragments with a Protein G column (GE Healthcare) and a Protein L column (Pierce, Rockford, IL). Fragment purity was checked by immunoblotting using anti-human IgG Fab or Fc-specific antibodies. (Jackson ImmunoResearch, West Grove, PA). Purity was judged to be greater

than 99%. The F4/80 antibody was from Serotec (Oxford, UK). The Ly 17.2 antibody was from Caltag (Burlingame, CA). Sheep anti-glomerular basement membrane (GBM) antiserum (nephrotoxic serum, NTS) was a gift from M. P. Madaio (University of Pennsylvania, Philadelphia, PA). Soluble Fc receptors containing a C-terminal hexahistidine tag were generated by transient transfection of 293T cells and purified from cell culture supernatants with Ni-NTA agarose as suggested by the manufacturer (Qiagen).

[0061] IVIG was treated with neuraminidase and the composition and structure of the resulting preparation was analyzed by mass spectroscopy. No detectable sialic acid containing glycans remained after neuraminidase treatment (Figure 4D, F and 5). These IgG preparations were then tested for their ability to protect mice from joint inflammation induced by passive transfer of KxN serum, an IgG 1 immune complex-mediated inflammatory disease model. De-sialylation with neuraminidase abrogated the protective effect of the IVIG preparation in the KxN serum induced arthritis model (Figure 4B, C, E). This loss of activity was not the result of reduced serum half-life of the asialylated IgG (Figure 6A) preparations or the result of changes to the monomeric composition or structural integrity of the IgG (Figure 6B). Removal of all glycans with PNGase had a similar effect and abrogated the protective effect of IVIG *in vivo* (Figure 4A). Selective removal of 2,6 sialic acid linkages abrogated IVIG activity, while removal of 2,3 linkages had no apparent effect (Figure 4G, H).

EXAMPLE 3. IVIG FRACTION WITH ENRICHED SIALIC ACID CONTENT DECREASES INFLAMMATION IN MOUSE ARTHRITIS MODEL

[0062] Preparation of IVIG with an increased content of sialic acid

[0063] Since sialic acid appeared to be required for the anti-inflammatory activity of IVIG, the basis for the high dose requirement (1 g/kg) for this anti-inflammatory activity could be the limiting concentration of sialylated IgG in the total IVIG preparation. The IVIG was fractionated on an SNA-lectin affinity column to obtain IgG molecules enriched for sialic acid modified glycan structures.

[0064] These sialic acid enriched fractions were tested for protective effects in the KxN serum transfer arthritis model as compared to unfractionated IVIG. A 10 fold enhancement in protection was observed for the SNA-binding fraction, such that equivalent protection was obtained at 0.1 g/kg of SNA-enriched IVIG as compared to 1 g/kg of unfractionated IVIG (Figure 4B, C). The serum half-life and IgG subclass distribution of the SNA enriched fraction was equivalent to that of unfractionated IVIG (Figure 7A, B). The effect of sialylation was specific to IgG; sialylated N-linked glycoproteins such as fetuin or transferrin with similar biantennary, complex carbohydrate structures had no statistically significant anti-inflammatory activity at equivalent molar concentrations of

IgG (Figure 8). Finally, the mechanism of protection of the sialylated IVIG preparation was similar to unfractionated IVIG in that it was dependent on FcγRIIB expression and resulted in the increased expression of this inhibitory receptor on effector macrophages (Figure 9).

EXAMPLE 4. THE INCREASED ANTI-INFLAMMATORY RESPONSE OF IVIG WITH INCREASED SIALIC ACID CONTENT IS MEDIATED BY SIALYLATION OF THE N-LINKED GLYCAN ON THE FC DOMAIN

[0065] Since the polyclonal IgG in IVIG may also contain O and N linked glycans on the light chains or heavy chain variable domains that can be sialylated, we confirmed that the increase in anti-inflammatory activity of the SNA-enriched IgG preparation resulted from increased sialylation of the N-linked glycosylation site on the Fc. Fc fragments were generated from unfractionated and SNA fractionated IVIG and tested for their *in vivo* activity. As observed for intact IgG, SNA-purified Fc fragments were enhanced for their protective effect *in vivo* when compared to Fc fragments generated from unfractionated IVIG (Figure 4C). In contrast, Fab fragments displayed no anti-inflammatory activity in this *in vivo* assay. Thus, the high dose requirement for the anti-inflammatory activity of IVIG can be attributed to the minor contributions of sialylated IgG present in the total preparation. Enrichment of these fractions by sialic acid binding lectin chromatography consequently increased the anti-inflammatory activity.

[0066] These results using passive immunization of IgG antibodies indicated that the ability of IgG to switch from a pro-inflammatory to an anti-inflammatory species is influenced by the degree of sialylation of the N-linked glycan on the Fc domain.

EXAMPLE 5. INCREASE OF ANTI-INFLAMMATORY ACTIVITY, MEDIATED BY SIALYLATION OF IgG, OCCURS DURING AN ACTIVE IMMUNE RESPONSE

Murine model for Goodpasture's Disease

[0067] In this model, mice are first sensitized with sheep IgG together with adjuvant and four days later injected with a sheep anti-mouse glomerular basement membrane preparation (nephrotoxic serum, NTS). Briefly, mice were pre-immunized intraperitoneally with 200 μg of sheep IgG (Serotec) in CFA, followed by intravenous injection of 2.5 μl of NTS serum per gram of body weight four days later. Blood was collected from non-treated control mice four days after the anti-GBM antiserum injection, and serum IgG was purified by Protein G (GE Healthcare, Princeton, NJ) and sepharose-bound sheep IgG column, generated by covalently coupling sheep IgG on NHS-activated sepharose column (GE Healthcare, Princeton, NJ), affinity chromatography.

[0068] Pre-sensitization followed by treatment with NTS induces mouse IgG2b anti-sheep IgG antibodies

(NTN immunized). Kaneko Y. et al., Exp. Med., 203:789 (2006). Mouse IgG2b antibodies are deposited in the glomerulus together with the NTS antibodies and result in an acute and fulminant inflammatory response by the IgG2b mediated activation of FcγRIV on infiltrating macrophages. In the absence of pre-sensitization inflammation is not observed, indicating that the mouse IgG2b anti-sheep IgG antibodies are the mediators of the inflammatory response.

[0069] To determine if active immunization resulting in pro-inflammatory IgG is associated with a change in sialylation, serum IgG and IgM from preimmune and NTS immunized mice were characterized for sialic acid content by SNA lectin binding Figure 10A,B,C). Total IgG sialylation was reduced on average by 40% in immunized mice as compared to the unimmunized controls. The effect was specific for IgG; sialylation of IgM was equivalent pre and post immunization. This difference in sialylation was more pronounced when the sheep specific IgG fraction from mouse serum was analyzed, showing a 50-60% reduction in sialylation compared to preimmune IgG (Figure 10B).

[0070] These results were confirmed by MALDI-TOF-MS analysis. Monosaccharide composition analysis was performed by UCSD Glycotechnology Core Resource (San Diego, CA). Glycoprotein samples were denatured with SDS and 2-mercaptoethanol, and digested with PNGase F. The released mixed N-glycans were purified by reversed-phase HPLC and solid-phase extraction, and then exposed hydroxyl groups of the N-glycans were methylated. The resulting derivatized saccharides were purified again by reversed-phase HPLC and subject to MALDI-TOF-MS.

[0071] The analysis of the pre and post immunization IgGs confirmed that the changes in the N-glycan structure were specific to the terminal sialic acids moieties (Figure 10C). The mouse IgG2b anti-sheep antibodies that were deposited in the glomeruli, previously shown to be responsible for engagement of the FcγRIV bearing, infiltrating macrophages displayed reduced sialic acid content as compared to the pre-immunized controls (Figure 10D).

[0072] All patent and non-patent publications cited in this disclosure are incorporated herein in to the extent as if each of those patent and non-patent publications was incorporated herein by reference in its entirety. Further, even though the invention herein has been described with reference to particular examples and embodiments, it is to be understood that these examples and embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the following claims.

CLAUSES:

[0073]

- 5 1. A polypeptide containing at least one IgG Fc region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody.
- 10 2. The polypeptide of clause 1 comprising a human IgG1, IgG2, IgG3 or IgG4 Fc region, said polypeptide having a higher sialic acid content as compared to an unpurified antibody.
- 15 3. The polypeptide of clause 1 or 2 having an increased anti-inflammatory activity *in vitro*.
- 20 4. The polypeptide of any one of clauses 1-3, having an increased anti-inflammatory activity *in vivo*.
- 25 5. The polypeptide of any one of clauses 1-4, derived from a naturally occurring antibody source.
- 30 6. The polypeptide of any one of clauses 1-4, derived from a recombinant antibody source.
- 35 7. The polypeptide of any one of clauses 1-6, having greater percent sialic acid content as compared to unmodified antibody, wherein said unmodified antibody comprises IVIG.
- 40 8. The antibody of any one of clauses 1-7, derived from a cell line having an enhanced protein sialylation activity.
- 45 9. The antibody of any one of clauses 1-8, modified by treatment with sialyltransferase.
- 50 10. The antibody of any one of clauses 1-9, which is purified.
- 55 11. A pharmaceutical formulation comprising the antibody of any clauses 1-10 in combination with a suitable carrier or diluent.
12. A method of preparation of a polypeptide containing at least one Fc region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxicity than an unpurified antibody, said method comprising:
 - providing an unpurified source of the polypeptide containing at least one Fc region, said unpurified source of the polypeptide containing at least one Fc region comprising a plurality of the polypeptides containing at least one Fc region having sialic acid and a plurality of the polypeptides containing at least one Fc region lacking sialic acid; and
 - increasing the ratio of the plurality of the polypeptides containing at least one Fc region having sialic acid to the plurality of the polypeptide containing at least one Fc region lacking sialic acid.
13. The method of clause 12, wherein said unpurified source of the polypeptide containing at least one Fc region comprises a human unpurified IgG antibody.
14. The method of clause 12 or 13, wherein the un-

purified source of the polypeptide containing at least one Fc region is provided from expressing a vector comprising a nucleic acid sequence in an expression system, wherein said nucleic acid sequence is translated into an IgG antibody.

15. The method of clause 14, wherein the expression system comprises modified host expression systems capable of N-linked glycosylation selected from the group consisting of fungal, plant, vertebrate and invertebrate expression systems, and any combinations thereof.

16. The method of any one of clauses 12-15, wherein the step of increasing the ratio of the plurality of the polypeptides containing at least one Fc region having sialic acid to the plurality of the polypeptides containing at least one Fc region lacking sialic acid is achieved through a removal of the polypeptides containing at least one Fc region lacking sialic acid.

17. The method of clause 16, wherein said removal is achieved by physical or chemical methods.

18. The method of clause 16 or 17 wherein said removal is achieved by a method selected from the group consisting of HPLC, lectin affinity chromatography, high pH anion exchange chromatography, and any combination thereof.

19. The method of any one of clauses 12-18, wherein the step of increasing the ratio of the plurality of the polypeptides containing at least one Fc region having sialic acid to the plurality of the polypeptides containing at least one Fc region lacking sialic acid is achieved through an enrichment of said unpurified source of the polypeptide containing at least one Fc region.

20. The method of clause 19 wherein said enrichment is achieved by a method selected from the group consisting of HPLC, lectin affinity chromatography, high pH anion exchange chromatography, and any combination thereof.

21. The method of clause 19 or 20 wherein said sialylation is achieved by a chemical reaction with an enzyme attaching sialic acid to a carbohydrate attached to the polypeptide containing at least one Fc region.

22. The method of clause 21, wherein the enzyme is α - (2,6)sialyltransferase.

Claims

1. A method of increasing the anti-inflammatory activity of a polypeptide containing at least one IgG Fc region, said method comprising:

providing a source of the polypeptide containing at least one IgG Fc region, said source of the polypeptide containing at least one IgG Fc region comprising a plurality of the polypeptide containing at least one IgG Fc region having sial-

ic acid and a plurality of the polypeptide containing at least one IgG Fc region lacking sialic acid; and

increasing the ratio of the plurality of the polypeptide containing at least one IgG Fc region having sialic acid to the plurality of the polypeptide containing at least one IgG Fc region lacking sialic acid.

2. The method of claim 1, wherein the polypeptide containing at least one IgG Fc region further includes a binding domain.
3. The method of claim 2, wherein the binding domain is an antibody variable domain or the extracellular domain of an FcR chain.
4. The method of claim 1, wherein the polypeptide containing at least one IgG Fc region is fused with other protein fragments or whole proteins.
5. The method of claim 4, wherein the other protein fragments or whole proteins is an immunoglobulin or an immunoglobulin fragment lacking an Fc region, or a biologically active protein or fragment thereof.
6. The method of claim 1, wherein the source of the polypeptide containing at least one IgG Fc region comprises an IgG antibody.
7. The method of claim 1, wherein the source of the polypeptide containing at least one IgG Fc region is IVIG.
8. The method of any of claims 1-7, wherein the step of increasing the ratio of the plurality of the polypeptides containing at least one IgG Fc region having sialic acid to the plurality of the polypeptides containing at least one IgG Fc region lacking sialic acid is achieved by subjecting the source of the polypeptide containing at least one IgG Fc region to an enzymatic reaction with an α -(2,6) sialyltransferase.
9. The method of any one of claims 1-8, wherein the step of increasing the ratio of the plurality of the polypeptides containing at least one IgG Fc region having sialic acid to the plurality of the polypeptides containing at least one IgG Fc region lacking sialic acid is achieved by *Sambucus nigra* lectin affinity column chromatography.
10. A polypeptide containing at least one IgG Fc region, IgG antibody or modified preparation of IVIG obtainable by the method of any preceding claim.
11. A modified preparation of IVIG with enriched sialic acid content, said preparation having a higher ratio of sialylated IgG Fc regions to asialylated IgG Fc

regions, as compared to the ratio of sialylated IgG Fc regions to asialylated IgG Fc regions in IVIG, wherein said modified preparation of IVIG at a dose of 0.1 mg/kg is **characterized by** an at least 10-fold increase in anti-inflammatory activity as measured at day 4 in a mouse K/BxN serum transfer arthritis model relative to IVIG.

- 5
12. The modified preparation of IVIG according to claim 11, obtainable by subjecting IVIG to an enzymatic reaction with α -(2,6) sialyltransferase and a donor sialic acid. 10
13. The polypeptide, IgG antibody or modified preparation of IVIG according to any preceding claim, for use in the treatment of an inflammatory disease. 15

20

25

30

35

40

45

50

55






Fig. 1


A



B



C



D

	FcγRIIB (K _d)	FcγRIII (K _d)	FcγRIV (K _d)
6A6-IgG1	4.0x10 ⁶	5.0x10 ⁵	n.b
6A6-IgG1 SA	3.9x10 ⁵	0.7x10 ⁵	n.b
6A6-IgG2b	3.9x10 ⁶	1.1x10 ⁶	2.9x10 ⁷
6A6-IgG2b SA	2.6x10 ⁵	0.5x10 ⁵	3.3x10 ⁶

FIG. 2





FIG. 3







FIG. 4



1. Fetuin 2. IVIG 3. α2-3 sialidase tx IVIG
4. α2-3,6 sialidase tx IVIG




FIG. 4 (continued)

Mass (m/z) (humam/mouse)	Composition
1835/1835	GlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
1865/1865	GalGlcNAc ₂ Man ₃ GlcNAc ₂
2040/2040	GalGlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
2070/2070	Gal ₂ GlcNAc ₂ Man ₃ GlcNAc ₂
2244/2244	Gal ₂ GlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
2401	Neu5AcGalGlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
2432	Neu5GcGal ₂ GlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
2490/2490	Gal ₂ GlcNAc ₂ Man ₃ (GlcNAc)GlcNAc ₂ Fuc
2606	Neu5AcGal ₂ GlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
2637	Neu5GcGal ₂ GlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
2851	Neu5AcGal ₂ GlcNAc ₂ Man ₃ (GlcNAc)GlcNAc ₂ Fuc
2882	Neu5GcGal ₂ GlcNAc ₂ Man ₃ (GlcNAc)GlcNAc ₂ Fuc
2965	Neu5Ac ₂ Gal ₂ GlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
3028	Neu5Gc ₂ Gal ₂ GlcNAc ₂ Man ₃ GlcNAc ₂ Fuc
3212	Neu5Ac ₂ Gal ₂ GlcNAc ₂ Man ₃ (GlcNAc)GlcNAc ₂ Fuc
3275	Neu5Gc ₂ Gal ₂ GlcNAc ₂ Man ₃ (GlcNAc)GlcNAc ₂ Fuc

FIG. 5





FIG 6




FIG. 7




FIG. 8






FIG. 9


A



B



C



D




FIG. 10



EUROPEAN SEARCH REPORT

Application Number
EP 18 18 8349

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	WO 96/39488 A1 (GENENTECH INC [US]; HOFFMANN LA ROCHE [CH]) 12 December 1996 (1996-12-12) * examples I-IV *	1-13	INV. A61K39/395 C07K16/00 C07K16/18 C12P21/08
A	WO 2005/063808 A1 (MERCK PATENT GMBH [DE]; GILLIES STEPHEN D [US]; LAUDER SCOTT [US]) 14 July 2005 (2005-07-14) * page 3 - page 59; examples 5B,6,8,10 *	1	
A	WO 2004/058944 A2 (SQUIBB BRISTOL MYERS CO [US]; SCHILLING BERNHARD M [US]; GANGLOFF SCOT) 15 July 2004 (2004-07-15) * example 2 *	1	
A	RAJU T SHANTHA ET AL: "Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 40, no. 30, 31 July 2001 (2001-07-31), pages 8868-8876, XP002461128, ISSN: 0006-2960 * table 1 *	1-13	
X	JASSAL R ET AL: "Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 AUG 2001, vol. 286, no. 2, 17 August 2001 (2001-08-17), pages 243-249, XP002574380, ISSN: 0006-291X * tables 1,2 *	10	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC) C07K A61K
Place of search Munich		Date of completion of the search 14 January 2019	Examiner Wagner, René
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.02 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 18 18 8349

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	WO 00/63403 A2 (INTROGENE BV [NL]; HATEBOER GUUS [NL]; VERHULST KARINA CORNELIA [NL];) 26 October 2000 (2000-10-26) * examples 16,19-24 *	1-13	
A	EP 1 020 528 A2 (SINAI SCHOOL MEDICINE [US]) 19 July 2000 (2000-07-19) * the whole document *	1-13	
A	QIU RUIQING ET AL: "Use of multidimensional lectin affinity chromatography in differential glycoproteomics.", ANALYTICAL CHEMISTRY 1 MAY 2005, vol. 77, no. 9, 1 May 2005 (2005-05-01), pages 2802-2809, XP002574381, ISSN: 0003-2700 * the whole document *	1-13	
A	HIGUCHI T ET AL: "CHARACTERIZATION OF THE RABBIT HOMOLOG OF HUMAN MUC1 GLYCOPROTEIN ISOLATED FROM BLADDER BY AFFINITY CHROMATOGRAPHY ON IMMOBILIZED JACALIN", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 10, no. 7, 1 January 2000 (2000-01-01), pages 659-667, XP002902597, ISSN: 0959-6658 * page 660 *	1-13	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 14 January 2019	Examiner Wagner, René
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03.02 (P04/C01)



EUROPEAN SEARCH REPORT

Application Number
EP 18 18 8349

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A,P	KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670-673, XP008076047, ISSN: 0036-8075 * the whole document *	1-13	TECHNICAL FIELDS SEARCHED (IPC)
A,P	SCALLON ET AL: "Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 7, 26 November 2006 (2006-11-26), pages 1524-1534, XP005792683, ISSN: 0161-5890 * the whole document *	1-13	
A,P	J. Axford; O. Fraser; S. Khan; A. Alavi; E. Tarelli; C. Sewell: "Presentation: Sialylation Differences between Different Commercial Preparations of Intravenous Immune Globulin (IVIG): Implications for Efficacy", American College of Rheumatology. 2007 Annual Scientific Meeting, 1 January 2007 (2007-01-01), page 1639, XP055097041, Retrieved from the Internet: URL:https://acr.confex.com/acr/2007/webprogram/Paper8243.html [retrieved on 2014-01-17] * the whole document *	1-13	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 14 January 2019	Examiner Wagner, René
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.02 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 18 18 8349

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9639488	A1	12-12-1996	AR 004940 A1 07-04-1999
			AR 011439 A2 16-08-2000
			AT 302266 T 15-09-2005
			AT 425245 T 15-03-2009
			AU 717847 B2 06-04-2000
			BG 63213 B1 29-06-2001
			BR 9609150 A 23-02-1999
			CA 2220684 A1 12-12-1996
			CN 1186514 A 01-07-1998
			CZ 9703909 A3 17-06-1998
			DE 69635076 D1 22-09-2005
			DE 69635076 T2 01-06-2006
			DK 0832189 T3 21-11-2005
			DK 1609853 T3 02-06-2009
			EA 199700364 A1 30-04-1998
			EP 0832189 A1 01-04-1998
			EP 1609853 A1 28-12-2005
			ES 2248812 T3 16-03-2006
			ES 2324046 T3 29-07-2009
			GE P20012519 B 10-05-2001
			HK 1017903 A1 27-05-2005
			HK 1087151 A1 27-11-2009
			HU 9900920 A2 28-07-1999
			IL 122398 A 23-12-2001
			IS 4626 A 03-12-1997
			JP 4348376 B2 21-10-2009
			JP H11507523 A 06-07-1999
			JP 2007190024 A 02-08-2007
			NO 975674 A 06-02-1998
			NZ 310202 A 28-10-1999
			OA 10753 A 11-12-2002
			PL 323737 A1 14-04-1998
PT 1609853 E 09-06-2009			
RO 120267 B1 30-11-2005			
SI 0832189 T1 28-02-2006			
SI 1609853 T1 31-08-2009			
SK 167097 A3 08-07-1998			
TR 199701543 T1 21-05-1998			
TW 426734 B 21-03-2001			
TW 516962 B 11-01-2003			
US 5705364 A 06-01-1998			
WO 9639488 A1 12-12-1996			
ZA 9604776 B 08-12-1997			
-----	-----	-----	-----
WO 2005063808	A1	14-07-2005	AU 2004309063 A1 14-07-2005
			BR P10417916 A 10-04-2007

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 18 18 8349

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		CA 2551916 A1	14-07-2005
		CN 1902222 A	24-01-2007
		DK 1699821 T3	16-07-2012
		EP 1699821 A1	13-09-2006
		ES 2387028 T3	12-09-2012
		JP 2008504008 A	14-02-2008
		JP 2012107042 A	07-06-2012
		KR 20060124656 A	05-12-2006
		PT 1699821 E	23-08-2012
		RU 2370276 C2	20-10-2009
		US 2005192211 A1	01-09-2005
		US 2009092607 A1	09-04-2009
		WO 2005063808 A1	14-07-2005

WO 2004058944	A2	15-07-2004	
		AT 488600 T	15-12-2010
		AU 2003303394 A1	22-07-2004
		BR 0316882 A	25-10-2005
		CA 2508925 A1	15-07-2004
		CN 1820080 A	16-08-2006
		CO 5590971 A2	30-12-2005
		CY 1111358 T1	05-08-2015
		DK 1576182 T3	21-02-2011
		EP 1576182 A2	21-09-2005
		ES 2354610 T3	16-03-2011
		HK 1075474 A1	12-08-2011
		IL 168873 A	30-04-2013
		JP 4496086 B2	07-07-2010
		JP 2006511224 A	06-04-2006
		KR 20050103466 A	31-10-2005
		MX PA05006522 A	17-02-2006
		PT 1576182 E	21-01-2011
		SI 1576182 T1	31-01-2011
		TW I328614 B	11-08-2010
		US 2005084933 A1	21-04-2005
		US 2008070280 A1	20-03-2008
		WO 2004058944 A2	15-07-2004

WO 0063403	A2	26-10-2000	
		AT 289354 T	15-03-2005
		AT 447617 T	15-11-2009
		AT 536417 T	15-12-2011
		AU 772352 B2	22-04-2004
		CA 2370477 A1	26-10-2000
		CN 1360638 A	24-07-2002
		CY 1109759 T1	10-09-2014
		DE 60018171 T2	29-12-2005
		DK 1161548 T3	23-05-2005

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 18 18 8349

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		DK 1533380 T3	01-02-2010	
		DK 2163640 T3	05-03-2012	
		EP 1161548 A2	12-12-2001	
		EP 1533380 A2	25-05-2005	
		EP 2163640 A1	17-03-2010	
		ES 2237420 T3	01-08-2005	
		ES 2335775 T3	05-04-2010	
		ES 2378272 T3	10-04-2012	
		HK 1048138 A1	12-06-2009	
		IL 145849 A	20-07-2009	
		JP 4210036 B2	14-01-2009	
		JP 2002541854 A	10-12-2002	
		MX PA01010360 A	05-04-2004	
		NO 20014977 A	17-12-2001	
		NZ 514951 A	27-02-2004	
		PT 1161548 E	30-06-2005	
		PT 1533380 E	09-02-2010	
		SI 1161548 T1	31-08-2005	
		SI 1533380 T1	31-03-2010	
		WO 0063403 A2	26-10-2000	

EP 1020528	A2	19-07-2000	AT 213020 T	15-02-2002
			AT 464386 T	15-04-2010
			AU 691795 B2	28-05-1998
			CA 2150555 A1	09-06-1994
			DE 69331550 D1	21-03-2002
			DE 69331550 T2	26-09-2002
			DE 122010000028 I1	12-08-2010
			DK 0670896 T3	27-05-2002
			DK 1942189 T3	07-06-2010
			DK 2210947 T3	07-10-2013
			EP 0670896 A1	13-09-1995
			EP 1020528 A2	19-07-2000
			EP 1942189 A2	09-07-2008
			EP 2210947 A2	28-07-2010
			ES 2168101 T3	01-06-2002
			ES 2344431 T3	26-08-2010
			ES 2431293 T3	25-11-2013
			IL 107814 A	31-12-2012
			IL 200005 A	30-09-2013
			JP 3598302 B2	08-12-2004
			JP 4005629 B2	07-11-2007
			JP H08503615 A	23-04-1996
			JP 2004121260 A	22-04-2004
			LU 91703 I2	24-08-2010
			LU 91704 I2	24-08-2010

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 18 18 8349

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2019

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		PT 670896 E	31-07-2002
		PT 1942189 E	28-05-2010
		PT 2210947 E	23-10-2013
		US 5401650 A	28-03-1995
		US 5580757 A	03-12-1996
		WO 9412628 A1	09-06-1994

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 60789384 B [0001]
- US 4816567 A [0031] [0033]
- US 6660843 B [0032]
- GB 8500392 W [0033]
- US 5225539 A [0034]
- US 3773919 A [0041]
- US 20060030521 A [0043]
- US 6656466 B [0046]
- US 20050181359 A [0047]

Non-patent literature cited in the description

- **DARON**. *Annu Rev Immunol*, 1997, vol. 15, 203-234 [0005] [0028]
- **WARD ; GHETIE**. *Therapeutic Immunol*, 1995, vol. 2, 77-94 [0005]
- **RAVETCH ; KINET**. *Annu Rev Immunol*, 1991, vol. 9, 457-492 [0005]
- **DEISENHOFER**. *Biochemistry*, 1981, vol. 20, 2361-2370 [0007]
- **FUJII et al.** *J. Biol. Chem*, 1990, vol. 265, 6009 [0009]
- **JEFFERIS ; LUND**. *Immune-1 Lett.*, 2002, vol. 82, 57 [0009]
- **SONDERMANN et al.** *J. Mol. Biol.*, 2001, vol. 309, 737 [0009]
- **NIMMERJAHN ; RAVETCH**. *Immunity*, 2006, vol. 24, 19 [0009] [0058]
- **SHIELDS et al.** *J. Biol. Chem.*, 2002, vol. 277, 26733 [0009]
- **NIMMERJAHN ; RAVETCH**. *Science*, 2005, vol. 310, 1510 [0009] [0055] [0060]
- **PAREKH et al.** *Nature*, 1985, vol. 316, 452 [0009]
- **RADEMACHER et al.** *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 6123 [0009]
- **HOLLAND et al.** *Biochim. Biophys. Acta*, 27 December 2005 [0009]
- **SHIKATA et al.** *Glycoconj. J.*, 1998, vol. 15, 683 [0009]
- **LASTRA et al.** *Autoimmunity*, 1998, vol. 28, 25 [0009]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. Public Health Service, National Institutes of Health, 1991 [0017]
- **BURTON**. *Mol Immunol*, 1985, vol. 22, 161-206 [0021]
- **RAVETCH ; KINET**. *Annu Rev Immunol*, 1991, vol. 9, 457-92 [0028]
- **CAPEL et al.** *Immunomethods*, 1994, vol. 4, 25-34 [0028]
- **DE HAAS et al.** *J Lab Clin Med*, 1995, vol. 126, 330-41 [0028]
- **NIMMERJAHN ; RAVETCH**. Ravetch Fc Receptors in Fundamental Immunology. 2006 [0028]
- **RAVETCH ; BOLLAND**. *Annu Rev Immunol*, 2001 [0028]
- **KOHLER ; MILSTEIN**. *Nature*, 1975, vol. 256, 495-497 [0031]
- **CLACKSON et al.** *Nature*, 1991, vol. 352, 624-628 [0031]
- **MARKS et al.** *J Mol Biol*, 1991, vol. 222, 581-597 [0031]
- **MORRISON et al.** *Proc Natl Acad Sci USA*, 1984, vol. 81, 6851-6855 [0033]
- **NEUBERGER et al.** *Nature*, 1984, vol. 312, 604-608 [0033]
- **TAKEDA et al.** *Nature*, 1985, vol. 314, 452-454 [0033]
- **JONES et al.** *Nature*, 1986, vol. 321, 522-525 [0034]
- **RIECHMANN et al.** *Nature*, 1988, vol. 332, 323-329 [0034]
- **PRESTA**. *Curr Op Struct Biol*, 1992, vol. 2, 593-596 [0034]
- **SAMBROOK ; RUSSEL**. *Molecular Cloning*, 2001 [0035]
- **STANLEY P. et al.** *Glycobiology*, 1996, vol. 6, 695-9 [0035]
- **WEIKERT S. et al.** *Nature Biotechnology*, 1999, vol. 17, 1116-1121 [0035]
- **ANDRESEN DC ; KRUMMEN L.** *Current Opinion in Biotechnology*, 2002, vol. 13, 117-123 [0035]
- **HIRABAYASHI et al.** *J Chromatogr B Analyt Technol Biomed Life Sci*, 2002, vol. 771, 67-87 [0035]
- **ROBERTSON ; KENNEDY**. *Bioseparation*, 1996, vol. 6, 1-15 [0035]
- **PATEL et al.** *Biochem J*, 1992, vol. 285, 839-845 [0035] [0046]
- **KUNKEL et al.** *Biotechnol Prog*, 2000, vol. 16, 462-470 [0035]
- **HAMILTON, SR et al.** *Science*, 2006, vol. 313, 1441 [0036]

EP 3 456 351 A1

- **LI, H et al.** *Nature Biotechnology*, 2006, vol. 24, 210 [0036]
- **WILDT,S ; GRENGROSS, TU.** *Nature Reviews Microbiology*, 2005, vol. 3, 119 [0036]
- Remington's Pharmaceutical Sciences. 1980 [0037] [0039]
- **WEN et al.** *J. Biol. Chem.*, 1992, vol. 267, 21011 [0044]
- **VAN DEN EIJDEN et al.** *J. Biol. Chem.*, 1991, vol. 256, 3159 [0044]
- **WEINSTEIN et al.** *J. Biol. Chem.*, 1982, vol. 257, 13845 [0044]
- **SASAKI et al.** *J. Biol. Chem.*, 1993, vol. 268, 22782-22787 [0044]
- **KITAGAWA ; PAULSON.** *J. Biol. Chem.*, 1994, vol. 269, 1394-1401 [0044]
- **KITAGAWA et al.** *J. Biol. Chem.*, 1996, vol. 271, 931-938 [0044]
- **KRZEWINSKI-RECCHI et al.** *Eur. J. Biochem.*, 2003, vol. 270, 950 [0045]
- **KUNKEL et al.** *Biotechnol. Prog.*, 2000, vol. 16, 462-470 [0046]
- **SAMBROOK ; RUSSEL.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Press, 2000 [0048]
- **WORMALD, MR et al.** *Biochem*, 1997, vol. 36, 1370 [0051]
- **NIMMERJAHN et al.** *Immunity*, 2005, vol. 23, 41 [0053] [0060]
- **DWYER.** *N. Engl. J. Med.*, 1992, vol. 326, 107 [0057]
- **IMBACH et al.** *Lancet*, 1981, vol. 1, 1228 [0057]
- **SAMUELSSON et al.** *Science*, 2001, vol. 291, 484 [0057]
- **BRUHNS et al.** *Immunity*, 2003, vol. 18, 573 [0057]
- **KANEKO et al.** *J. Exp. Med.*, 2006, vol. 203, 789 [0057]
- **KANEKO Y. et al.** *Exp. Med.*, 2006, vol. 203, 789 [0060] [0068]